JP Patent

JP2024501235A — レボドパ投薬レジメン

Assigned to Amneal Pharmaceuticals LLC · Expires 2024-01-11 · 2y expired

What this patent protects

本発明は、パーキンソン病患者の治療に使用するための制御放出レボドパ組成物の経口投薬レジメンを提供する。

USPTO Abstract

本発明は、パーキンソン病患者の治療に使用するための制御放出レボドパ組成物の経口投薬レジメンを提供する。

Drugs covered by this patent

Sinemet Cr (CARBIDOPA) · Aton

Patent Metadata

Patent number: JP2024501235A
Jurisdiction: JP
Classification: —
Expires: 2024-01-11
Drug substance claim: No
Drug product claim: No
Assignee: Amneal Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.